ACR Releases Summary of MedPAC March Report
Highlighting MedPACās March findings on Medicare spending, payment adequacy, and key recommendations for physicians and hospitals.
Read moreMain Content
ACR Congratulates Sirtex Medical on FDA Approval of Its SIR-Spheres to Treat Liver Cancer
The ACR-managed clinical trial was a key part of the approval effort.
Aug. 6, 2025
The ACR® Center for Research and Innovation (CRI®) served as the imaging contract research organization for the DOORwaY90 clinical trial that contributed to FDA approval of Sirtex SIR-Spheres technology for liver cancer treatment.
CRI’s management of image and data collection, quality control, and central review of 600 CT/MRI scans from 65 subjects across 12 sites using five expert reviewers was critical to the success of the trial.
Interim analysis of the DOORwaY90 trial revealed that 98.5% of patients had the Best Overall Response Rate through nine months and 100% of all evaluable patients were able to demonstrate local tumor control.
